Instituto de Investigación de la Cadena Láctea (INTA-CONICET), Estación Experimental Agropecuaria Rafaela, Ruta 34, km 227, Rafaela, Santa Fe CP 2300, Argentina.
Instituto de Investigación de la Cadena Láctea (INTA-CONICET), Estación Experimental Agropecuaria Rafaela, Ruta 34, km 227, Rafaela, Santa Fe CP 2300, Argentina.
Acta Trop. 2024 Sep;257:107319. doi: 10.1016/j.actatropica.2024.107319. Epub 2024 Jul 5.
Bovine brucellosis is a zoonotic disease caused by Brucella abortus, responsible for abortions in cows. It is endemic in low- and middle-income countries, where the brucellosis control and eradication programs are based on compulsory vaccination, detection of infected cattle through serologic assays, and culling of infected animals at slaughterhouses. The development of high sensitivity and specificity, and low-cost serologic assays guarantee their implementation in countries where the disease is endemic. The aim of the present study was to develop and validate a competitive inhibition enzyme-linked immune assay (ciELISA) to detect anti-B. abortus antibodies in sera from cattle. The developed ciELISA was validated using 2833 serum samples from dairy and beef cattle. From these, 1515 sera were from uninfected cows that belonged to free of brucellosis herds and 1318 were from infected cows that belonged positive to brucellosis herds. Sera were analyzed with the developed ciELISA, the buffer plate antigen (BPA) test, and the complement fixation test (CFT). The brucellosis status of the herds was officially established according to the country legislation and consistent for at least 5 years and was defined for each cow using the CFT as gold standard. The cutoff for the ciELISA was calculated using a ROC curve and its sensitivity and specificity were analyzed using the Bayesian Latent Class Model (BLCM) approach. The agreement among tests was calculated using the kappa (κ) value. In addition, 15 calves were vaccinated with 3 × 10 viable cells of B. abortus Strain 19 vaccine, and the dynamics of antibodies were measured by CFT, buffered plate antigen (BPA) test, and the developed ciELISA. The obtained cutoff for ciELISA was ≥ 47 percentage of inhibition (% I), at the BLCM approach the sensitivity was 99.01 % (95 % CI: 97.55-100) and the specificity 98.74 % (95 % CI: 97.68-99.8). The κ between the ciELISA and BPA was κ = 0.88 and between the ciELISA and CFT κ = 0.95. Antibodies against B. abortus were detected in all the vaccinated calves 7 days after vaccination (AV) by the three assays, at day 135 AV all the calves were negative to CFT (15/15), 93.3 % (14/15) to ciELISA and 73.3 % (11/15) to BPA, and at day 190 AV all the calves were negative to the three assays. The developed ciELISA showed a very good performance, could detect the majority of vaccinated animals as negative after 135 days and could be used for the detection of anti-B. abortus antibodies in serum samples for the brucellosis control and eradication program.
牛布鲁氏菌病是一种由布鲁氏菌流产亚种引起的人畜共患病,可导致奶牛流产。它在中低收入国家流行,这些国家的布鲁氏菌病控制和根除计划基于强制性疫苗接种、通过血清学检测发现感染牛,以及在屠宰场扑杀感染动物。高灵敏度、特异性和低成本的血清学检测方法的发展确保了它们在疾病流行的国家得到实施。本研究旨在开发和验证一种竞争抑制酶联免疫吸附试验(ciELISA),以检测牛血清中的抗布鲁氏菌抗体。使用来自奶牛和肉牛的 2833 份血清样本对开发的 ciELISA 进行了验证。其中,1515 份血清来自未感染的奶牛,这些奶牛来自无布鲁氏菌病牛群,1318 份血清来自来自布鲁氏菌病阳性牛群的奶牛。使用开发的 ciELISA、缓冲平板抗原(BPA)检测和补体结合试验(CFT)对血清进行分析。根据国家立法,牛群的布鲁氏菌病状况至少 5 年来一直保持稳定,并使用 CFT 为每头奶牛确定,作为金标准。使用 ROC 曲线计算 ciELISA 的截断值,并使用贝叶斯潜在类别模型(BLCM)方法分析其敏感性和特异性。使用κ值计算检测之间的一致性。此外,15 头小牛接种了 3×10 个活的布鲁氏菌流产菌株 19 疫苗细胞,通过 CFT、缓冲平板抗原(BPA)检测和开发的 ciELISA 测量抗体的动态变化。ciELISA 的截断值为≥47%抑制率(%I),BLCM 方法的灵敏度为 99.01%(95%CI:97.55-100),特异性为 98.74%(95%CI:97.68-99.8)。ciELISA 与 BPA 之间的κ值为κ=0.88,ciELISA 与 CFT 之间的κ值为κ=0.95。三种检测方法均在接种后 7 天(AV)检测到所有接种小牛的布鲁氏菌抗体,在 AV 第 135 天,所有小牛的 CFT 均为阴性(15/15),ciELISA 为 93.3%(14/15),BPA 为 73.3%(11/15),在 AV 第 190 天,所有小牛的三种检测均为阴性。开发的 ciELISA 表现出非常好的性能,可在 135 天后检测到大多数接种动物为阴性,可用于布鲁氏菌病控制和根除计划中检测血清样本中的抗布鲁氏菌抗体。